These Stocks under $10 Are Poised To Explode

Published on December 21, 2023 at 4:13 pm by Swati Goyal in Hedge Funds, News

In this piece, we will take a look at these stocks under $10 are poised to explode. If you want to skip our introduction to these tricky stocks, jump to These 5 Stocks Under $10 Are Poised To Explode.

The US equity markets remain on track for a strong finish in 2023 as major indices hover near all-time highs. Easing inflation and a resilient economy that has avoided recession are factors that have catapulted the markets higher for the better part of the year. Will the rally continue into 2024? That’s the big question amid a wave of monetary and deteriorating macroeconomic uncertainties.

With the Federal Reserve indicating rate cuts in 2024, investors’ risk appetite is going to increase in the next year and small companies trading for low prices will come on investors’ radar. In this backdrop it would be interesting to see which under-$10 stocks have strong upside potential.

A close up shot of a stock ticker reflecting the performance of Indian equity markets.

Our Methodology

For this article we picked 10 stocks under $10 which have bullish ratings from analysts and price targets that show strong upside potential from their current levels. For each stock we have also mentioned hedge fund sentiment. Hedge funds’ top 10 consensus stock picks outperformed the S&P 500 Index by more than 140 percentage points over the last 10 years (see the details here). That’s why we pay very close attention to this often-ignored indicator.

These Stocks under $10 Are Poised To Explode

10. Annovis Bio, Inc. (NYSE:ANVS)

Share Price as of December 14: $9.70

Share Price Upside Potential: 230.39%

Number of Hedge Funds: 2

Annovis Bio, Inc. (NYSE:ANVS) is a cheap stock under $10 for anyone eyeing exposure in the healthcare sector. It operates as a clinical-stage drug platform that develops drugs for treating neurodegeneration conditions. Buntanetap, the lead product of Annovis Bio, Inc. (NYSE:ANVS), is in phase 3 trials for chronic neurodegenerative diseases like Alzheimer’s and Parkinson’s.

While Annovis Bio, Inc. (NYSE:ANVS) is down by 30% for the year, it has started showing signs of edging higher after bottoming out of all-time lows. The stock has exploded in recent weeks as its lead drug, Buntanetap, undergoes late-stage study in patients with Parkinson’s disease. Consensus estimates on Wall Street indicate Annovis Bio, Inc. (NYSE:ANVS) is a Strong Buy with a $30.33 price target, implying 230.39% upside potential.

Insider Monkey’s Q3 2023 survey of 910 hedge funds revealed that two had invested in Annovis Bio, Inc. (NYSE:ANVS).

9. ESSA Pharma Inc. (NASDAQ:EPIX)

Share Price as of December 14: $5.68

Share Price Upside Potential: 233.27%

Number of Hedge Funds: 12

ESSA Pharma Inc. (NASDAQ:EPIX) is a clinical-stage pharmaceutical company that focuses on the development of small-molecule drugs for the treatment of prostate cancer. ESSA Pharma Inc. (NASDAQ: EPIX)’s lead product is EPI-7386, an androgen receptor-based resistance mechanism that develops in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.

After being consolidated for the better part of the year, ESSA Pharma Inc. (NASDAQ: EPIX) exploded in the second half and is up by about 114%. Analysts expect the rally to persist into 2024, going by the Buy rating and $18.33 price target, implying 233.27% upside potential.

ESSA Pharma Inc. (NASDAQ:EPIX) is getting the attention of smart money, as 12 elite hedge funds held stakes in the company in the third quarter of 2023.

8. electroCore, Inc. (NASDAQ:ECOR)

Share Price as of December 14: $5.50

Share Price Upside Potential: 236.54%

Number of Hedge Funds: 1

electroCore, Inc. (NASDAQ:ECOR) is another stock under $10 poised to explode, which is ideal for gaining exposure in the healthcare sector. electroCore, Inc. (NASDAQ:ECOR) operates as a commercial-stage bioelectronics medicine and wellness company.

electroCore, Inc. (NASDAQ:ECOR) has gained about 35% year to date, outperforming the S&P 500, which is up by about 21%. Likewise, analysts on Wall Street are overly optimistic about electroCore, Inc. (NASDAQ:ECOR), with a Buy rating and a $17.50 price target, implying a 236.54% upside potential. One hedge fund was long electroCore, Inc. (NASDAQ:ECOR) in the third quarter of 2023.

7. Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)

Share Price as of December 14: $1.31

Share Price Upside Potential: 237.41%

Number of Hedge Funds: 10

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) is another cheap stock under $10 poised to explode, operating as a clinical-stage pharmaceutical company that develops and commercializes therapies for people with rare genetic mitochondrial diseases. REN001, the lead product of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), is a strong and specific drug that activates a protein involved in energy metabolism. It is being tested for inherited diseases that affect the mitochondria.

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)’s been one of the best-performing cheap stocks in 2023, rallying by about 204%. Similarly, analysts on Wall Street expect the rally to persist into 2024, going by a $24.26 price target, implying a 237.41% upside potential.

By the end of this year’s September quarter, 10 out of the 910 hedge funds provided by Insider Monkey had acquired and held shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM).

6. Zepp Health Corporation (NYSE:ZEPP)

Share Price as of December 14: $1.51

Share Price Upside Potential: 238.67%

Number of Hedge Funds: 3

Zepp Health Corporation (NYSE:ZEPP) is an innovative wearable and health technology company. The company empowers people to live lives by optimizing health, fitness, and wellness journeys through its consumer brands Amazfit, Zepp Clarity, and Zepp Aura. Zepp Health Corporation (NYSE:ZEPP) offers AI chips, biometric sensors, and data algorithms for its cloud-based actionable insights.

Zepp Health Corporation (NYSE:ZEPP) is up by about 3.4% for the year as analysts on Wall Street rate it as a buy with a $5.08 price target, implying a 238.67% upside potential. Zepp Health Corporation (NYSE:ZEPP) trades at highly discounted levels, going by the 5.13 price-to-earnings ratio.

According to Insider Monkey’s third-quarter database, three hedge funds were bullish on Zepp Health Corporation (NYSE:ZEPP), the same as the previous quarter.

Click to continue reading and see The 5 Stocks Under $10 That Are Poised To Explode.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on November 14, 2025 at by Inan Dogan, PhD

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

175 Teslas
107 Amazons
140 Metas
84 Googles
65 Microsofts
And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

These Stocks under $10 Are Poised To Explode

Published on December 21, 2023 at 4:13 pm by Swati Goyal in Hedge Funds, News

These Stocks under $10 Are Poised To Explode

10. Annovis Bio, Inc. (NYSE:ANVS)

9. ESSA Pharma Inc. (NASDAQ:EPIX)

8. electroCore, Inc. (NASDAQ:ECOR)

7. Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)

6. Zepp Health Corporation (NYSE:ZEPP)

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on November 14, 2025 at by Inan Dogan, PhD